Betamethasone inhibits tumor development, microvessel density and prolongs survival in mice with a multiresistant adenocarcinoma TA3

Biological Research

Volumn 43, Issue 3, 2010, Pages 317-322

  Garrido, Osvaldo ^a   Letelier, René ^a   Rosas, Carlos ^a   Fuenzalida, Marcela ^a   Ferreira, Arturo ^a   Lemus, David ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Angiogenesis; Betamethasone treatment; Metastasis

Indexed keywords

ANIMALIA; MUS; TRYPANOSOMA CRUZI;

EID: 78650041149     PISSN: 07169760     EISSN: 07176287     Source Type: Journal    
DOI: 10.4067/S0716-97602010000300008     Document Type: Article

References (53)

1. ADAMS RH, ALITALO K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nature Rev Mol Cell Biol 8: 464-478.
2. AMSTERDAM A, TAJIMA K, SASSON R (2002) Cell-specific regulation of apoptosis by Glucocorticoids: implications to their anti-inflammatory action. Biochem Pharmacol 64 (5-6): 843-850.
3. ARANDA E, OWEN G (2009) A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using EA.hy926 endothelial cell line. Biol Res 42: 263-389.
4. AVRAAMIDES CJ, GARMY-SUSINI B, VARNER JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617.
5. BANCIU M, SCHIFFELERS R, FENS M, METSELAAR J, STORM G (2006) Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Releases 113 (1): 1-8.
6. BANCIU M, SCHIFFELERS R, METSELAAR J, STORM, G (2008) Utility of Targeted Glucorticoids in Cancer Therapy. J Liposome Res 18: 47-57.
7. BOUCK N, STELLMACH V, HSU SC (1996) How tumors become angiogenic. Adv Cancer Res 69: 135-174.
8. BROWN LF, DETMAR M, CLAFFEY K, NAGY JA, FENG D, DVORAK AM, DVORAK HF (1997) Vascular permeability factor/VEGF: a multifunctional angiogenic cytokine. EXS 79: 233-269.
9. BROWN JM, WILSON WR.(2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
10. BUSCHMAN I, SCHAPER W (2000) The pathophysiology of the collateral circulation. J Pathol 190: 338-342.
11. BUTTGEREIT F, WEHLING M, BURMESTER GR (1998) A new hypothesis of modular glucocorticoid actions. Arthritis & Rheumatism 41: 761-767.
12. BUTTGEREIT F, STRAUB RH, WEHLING M, BURMESTER GR (2004) Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 50: 3408-3417.
13. CARMELIET P (2000) Mechanism of angiogenesis and arteriogenesis. Nature Med 6: 389-395.
14. CARMELIET P (2005) Angiogenesis in life, disease and medicine. Nature 42: 932-936.
15. CHENG T, CAO W, WEN R, STEINBERG R, LAVAIN M (1998) Prostaglandin E2 induces VEGF and FGFb mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis 39: 581-591.
16. CROXTALL JD, VAN HAL PT, CHOUDHURY Q, GILROY DW, FLOWER RJ (2002) Different glucocorticoids vary in their genomic and no genomic mechanism of action in A549 cells. Br J Pharmacol 135: 511-519.
17. FAROOQUI M, GENG ZH, STEPHENSON EJ, YEE D, GUPTA K (2006) Naloxone acts as an antagonist of estrogen receptor in MCF7 cancer cells. Mol Cancer Ther 5: 611-620.
18. FERREIRA V, MOLINA CM, SCHWAEBLE W, LEMUS D, FERREIRA A (2005) Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis? Trends Parasitol 21(4): 169-174.
19. FOLKMAN J (1971) Tumor angiogenesis: Therapeutic implications. NEJM 285: 1182-1186.
20. FOLKMAN J, LANGER R, LINHARDT RJ, HAUDENSCHILD C, TAYLOR S (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science, 221: 779.
21. FOLKMAN J (2000) In cancer medicine (eds. Holland, J.F. et. Al.) 132-152 (Decker, Ontario, Canada).
22. FORSYTHE JA, JIANG BH, IYER NV, AGANI F, LEUNG SW, KOOS RD, SEMENZA GL (1996) Activation of VEGF gene transcription by Hipoxia-Inducible factor 1. Mol Cell Biol 16: 4604-4613.
23. GAJARDO P, CORDANO G, PAVANI M, MUÑOZ S, RIVERA E, MEDINA J, GUERRERO A, FERREIRA J (2001) La inhibición de la respiración mitocondrial por el éster 2,6-Dihidroxi-4-Carboxifenoxiacetato de bis isopropilo (CARFENISTOP) y su papel como restaurador de la sensibilidad a fármacos antineoplásicos en el carcinoma multiresistente TA3-MTX-R transplantable de ratón. Rev Chi Cancerología y Hematología 11: 162-174.
24. GRIFFIOEN A, MOLEMA G (2000) Angiogenesis: Potentials of pharmacologic intervention in the treatment of cancer, cardiovascular diseases and chronic inflammation. Pharmac Rev 52 (2): 237-267.
25. HANAHAN D, WEINBERG R (2000) The hallmarks of Cancer. Cell 100: 57-100.
26. HÖPER MM, VOELKEL NF, BATES TO, ALLARD JD, HORAN M, SHEPHERD D, TUDER RM (1997) Prostanglandins induce VEGF in a human monocytic cell and rat lung via camp. Am J Respir Cell Mol Biol 17: 748-756.
27. ILLANES J, DABANCENS A, ACUÑA O, FUENZALIDA M, GUERRERO A, LOPEZ C, LEMUS D (2002) Effect of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse. Biol Res 35: 339-345.
28. KOLENSNIK RN, KRANKE M (1998) Reg. of ceramide production and apoptosis. Ann Rev Physiol 60: 643-665.
29. KROEMER G, DALLAPORTA B, AND RESCHE-RIGON M (1998) The mitocondrial death/Life regulations in apoptosis and necrosis. Ann Rev Physiol 60: 619-642.
30. LEMUS D, DABANCENS A, ILLANES J, FUENZALIDA M, GUERRERO A, LÓPEZ C (2001) Antiangiogenic effect of betametasona on the chick CAM stimulated by TA3 tumor supernatant. Biol Res 34: 227-236.
31. LIN EY, POLLARD JW (2007) Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67: 5064-5066.
32. LIOTTA LA, KOHN EC (2001) The microenvironment of the tumor - host interface. Nature 411: 375-379.
33. LÓPEZ N, VALCK C, RAMÍREZ G, RODRÍGUEZ M, RIBEIRO C, ORELLANA J, MALDONADO I, ALBINI A, ANACONA D, LEMUS D, AGUILAR L, SCHWAEBLE W, FERREIRA A (2010). Trypanosoma cruzi calreticulin mediates key antiangiogenic effects of non endothelial cells. PLos Neglected Tropical Diseases. (In Press).
34. LUBET R, TAO L, WANG W, KRAMER P, PERREIRA M. (2004) Effects of budesonide on overall 5-methylcytosine levels and specific methylation and messenger RNA expression of the insuline-like growth factor II gene in mouse lung tumors. Chest 125: 157S.
35. MALONNE H, LANGER I, KISS R, ATASSI G (1999) Mechanism of tumor angiogenesis and therapeutic implications: angiogenesis inhibitor. Clin Exp Met 17: 1-41.
36. MOLINA MC, FERREIRA V, VALCK C, AGUILAR L, ORELLANA J, ROJAS A, RAMIREZ G, BILLETTA R, SCHWAEBLE W, LEMUS D, FERREIRA A. (2005). An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis. Mol. Biochem. Parasitol. 140: 133-140.
37. ÓREILLY MS, HOLMGREN L, SHING Y, CHEN C, ROSENTHAL RA, CAO Y, MOSES M, LANE WS, SAGE EH, FOLKMAN L (1994) Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. En: Cold Springs Harbor Symposiaon quantitative Biology 59: 471-482.
38. ÓREILLY MS, BOEHM T, SHING Y, FUKAI N, VASIOS G, LANE WS, FLYNN E, BIRKHEAD JR, OLSEN BR, FOLKMAN J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
39. PENHALIGON M, CAMPLEJOHN RS (1985) Combination heparin plus cortisone treatment of two transplanted tumors in C3H/He mice. J Natl Cancer Inst. 74: 689.
40. PIKE SE, YAO L, SETSUDA J, et al. (1999). Calreticulin and calreticulin fragments are endotelial cell inhibitors that suppress tumor growth. Blood 94: 2461-2468.
41. PLAZA C, PAVANI M, ARAY-AMATURANA R, PEZOA J, MAYA JD, MORELLO A, BECKER MI, DE IOANNES A, FERREIRA J (2009) Chemosensitizing effect of nordihydroguaiaretic acid and its tetraacetylated derivative on parental and multiresistant TA3 mouse mammary adenocarcinoma cells. In Vivo Nov-Dec; 23(6): 959-967.
42. PLAZA C, PAVANI M, FAUNDEZ M, MAYA JD, MORELLO A, BECKER MI, DE IOANNES A, CUMSILLE MA, FERREIRA J (2008) Inhibitory effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on respiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3MTX-R. In Vivo May-Jun; 22(3): 353-361.
43. REICHENSTEIN M, REICH R, LEHOUX JG, HANUKOGLU I. (2004) ACTH induces TIMP-1 expression and inhibits collagenase in adrenal cortex cells. Mol Cell Endocrinol 215: 109-114.
44. SCHIFFELERS RM, METSELAAR JM, FENS MH, JANSSEN AP, MOLEMA G, STORM G. (2005) Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia 7: 118.
45. SCHMID MC, VARNER JA (2007) Myeloid cell trafficking and tumor angiogenesis. Cancer Lett 250: 1-8.
46. SCHMIDT S, RAINER J, PIONER C, PRESUL E, RIML S, KOFLER R (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ (Suppl 1): 45-55.
47. SCHOLZEN T, GERDES J (2000) The Ki-67 Protein: From the Known and the Unknown. J Cell Physiol 182: 311-322.
48. SMOAK KA, CIDLOWSKI JA (2004) Mechanisms of glucocorticoids receptor signaling during inflammation. Mech Ageing Dev 125: 697-706.
49. STRAUSS L, FUENZALIDA M, ILLANES J, DABANCENS A, DIAZ A, LEMUS D, GUERRERO A (2002) Effect of sulfated b-cyclodextrin, a water soluble cycloamylose, on the promotion and/or inhibition of angiogenesis. Pathol Oncol Res 8: 47-53.
50. VASSILIOU E, SHARMA V, JING H, SHEIBANIE F, GANEA D. (2004) Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells. J Immunol 173: 6955-6964.
51. YANG EV, BANE CM, MACCALLUM RC, KIECOLT-GLASER JK, MALARKEY WB, GLASER R (2002) Stress-related modulation of matrix metalloproteinase expression. J Neuroimmunol 133: 144.
52. ZIPPER J, DABANCENS A, GUERRERO A, TRUJILLO V (1995) Quinacrine Revised. Human Reprod Update 1 (4): 324-342.
53. ZUÑIGA J, FUENZALIDA M, GUERRERO A, DIAZ E, LEMUS D (2003) Effects of steroidal and non steroidal drugs on the revascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res 36: 233-240